Pharmaceutical Technology
DECEMBER 16, 2022
The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. of 7MM sales.
Pharma Marketing Network
MAY 3, 2023
Pharmaceutical marketing is a critical aspect of the industry, as it helps in spreading awareness about the benefits and potential side effects of different drugs. In conclusion, navigating the regulatory environment of pharmaceutical marketing requires a delicate balance between patient safety and industry innovation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
AUGUST 16, 2022
The regulator confirmed that the vaccine meets its standards of safety, quality and effectiveness. In each dose of the booster vaccine, ‘Spikevax bivalent Original/Omicron’, half of the vaccine (25µg) targets the original virus strain from 2020 and the other half (25µg) targets the Omicron variant.
Pharmaceutical Technology
AUGUST 15, 2022
After the vaccine was found to meet the standards of safety and quality, the regulatory agency granted the authorisation. According to the safety monitoring, side effects were generally mild and self-resolving, as well as in line with those reported for the original Moderna booster dose. 1 Omicron variant of concern.
World of DTC Marketing
FEBRUARY 4, 2021
million in 2020, more than double the number in 2015, according to health data company IQVIA. The company decided there were too few reports of serious depression and suicidal behavior and not enough specifics about those cases to warrant more than “routine” monitoring of safety data. Annual U.S.
World of DTC Marketing
DECEMBER 23, 2020
During the first quarter of 2020, the number of telehealth visits increased by 50%, compared with the same period in 2019, with a 154% increase in visits noted in surveillance week 13 in 2020, compared with the same period in 2019. What are the side effects? That belief is out the window.
Pharmaceutical Technology
JANUARY 27, 2023
Briumvi is the third approved injectable MS treatment directed against CD20 antigen expressed on B cells, with the other therapies being Kesimpta (ofatumumab, approved in 2020) and Ocrevus (ocrelizumab, approved in 2017). All three treatments are monoclonal antibodies. Some 48% of patients on Briumvi also suffered with infusion reactions.
Expert insights. Personalized for you.
59 
Let's personalize your content